natgillin/translations-raw huggingface dataset:
POLY1 is a first poly(ethylene glycol) having a weight average molecular weight in the range of greater than 5,000 Daltons to 100,000 Daltons; 
[image] POLY1 je prvi poli(etilen glikol) koji ima molekularnu težinu u rasponu od više od 5,000 Daltona do 100,000 Daltona;
is a first spacer moiety; 
H je ionizirajući atom vodika;
Re2, when present, is a second electron altering group; 
Re2, kada je prisutan, je druga skupina koja mijenja elektron; i
An apparatus as claimed in claim 2, characterized in that each of said rectilinear grooves (1 a, 1 b, 10a / 10b) of said first panel (1) is provided with a regularly spaced series of transversal partitions (1 a', 1 b' / 10a', 10b'), having height lower than depth of the same grooves. 
Sustav prema tvrdnjama iz zahtjeva 2, naznačen time da je svaki od pravocrtnih utora (1a, 1b, 10a/10b) prve ploče (1) izveden s nizom pravilno razmaknutih poprečnih pregrada (1a’, 1b’ / 10a’, 10b’), čija je visina manja od dubine tih utora.
An apparatus according to one or more of the preceding claims, characterized in that said panel (1) is provided on the lower side with multiple pairs of tubular seats (32) with vertical axis in the proximity of its front and back longitudinal edges. 
Sustav prema jednom ili više prethodnih zahtjeva, naznačen time da spomenuta ploča (1) na svojoj donjoj strani ima više parova cjevastih sjedišta (32) s okomitom osi u blizini njenih prednjih i stražnjih uzdužnih rubova.
An apparatus according to one or more of the preceding claims, characterized in that said panel (1)is provided with a seat (1 a") obtained at the front end of the central transversal groove (1 a) provided on the upper side and an identical seat at the front end of the transversal groove (10a) provided on the lower side. 
Sustav prema jednom ili više prethodnih zahtjeva, naznačen time da se na spomenutoj ploči (1) nalazi jedno sjedište (1a") izvedeno na prednjem kraju središnjeg poprečnog utora (1a) koji se nalazi na gornjoj strani i jedno identično sjedište na prednjem kraju poprečnog utora (10a) izvedenog na donjoj strani.
An apparatus according to one or more of the preceding claims, characterized in that said top (16) is provided with a seat (100a") obtained at the front end of the central transversal groove (100a) provided on the lower side. 
Sustav prema jednom ili više prethodnih zahtjeva, naznačen time da se na spomenutoj gornjoj plohi (16) nalazi jedno sjedište (100a") izvedeno na prednjem kraju središnjeg poprečnog utora (100a) izvedenog na donjoj strani.
An apparatus as claimed in one or more of claims 19 to 21, characterized in that said first finishing strip (22) is provided with a handle (23) in external position on the second longitudinal edge (22c). 
Sustav prema jednom ili više od zahtjeva 19 do 21, naznačen time da spomenuta prva završna letvica (22) ima jednu ručku (23) na vanjskom položaju na drugom uzdužnom rubu (22c).
An apparatus as claimed in one or more of claims 19 to 22, characterized in that said first connection strip (25) is provided with a handle (23) in external position on the second longitudinal edge (25c). 
Sustav prema jednom ili više od zahtjeva 19 do 22, naznačen time da spomenuta prva spojna letvica (25) ima jednu ručku (23) na vanjskom položaju na drugom uzdužnom rubu (25c).
An apparatus according to one or more of claims 19 to 24, characterized in that said first finishing strip (22) and said first connection strip (25) are provided in the front with an eye (200) in the proximity of the corresponding handles (23). 
Sustav prema jednom ili više od zahtjeva 19 do 24, naznačen time da spomenuta prva završna letvica (22) i spomenuta prva spojna letvica (25) na prednjoj strani imaju jedno okce (200) u blizini pripadajućih ručki (23).
An apparatus as claimed in claim 28, characterize in that each of said radial plugs (S) is formed of two converging arms (21c) connected at the ends by means of an elastically compressible basically V-shaped bridge (21 c) and also provided at the ends with a tooth (21 d) in perpendicular position. 
Sustav prema tvrdnjama iz zahtjeva 28, naznačen time da svakog od spomenuta dva radijalna zatika (S) tvore dva konvergirajuća kraka (21c) koji su na krajevima spojeni elastičnim mostom (21c) u obliku slova „V“ koji se može pritisnuti i na krajevima također imaju jedan zubac (21d) u okomitom položaju.
An apparatus according to claim 18, characterized in that said door (18) is provided with an empty structure internally stiffened by transversal ribbing (N) with vertical direction. 
Sustav prema zahtjevu 18, naznačen time da spomenuta vrata (18) imaju jednu praznu strukturu koja je iznutra učvršćena poprečnim rebrima (N) okomitog smjera.
An ex-vivo method for testing whether a patient will respond therapeutically to a method of treatment comprising administration of an immunogenic composition, wherein the testing method comprises the step of measuring levels of sICAM-1 in a blood sample obtained from said patient before administration of said immunogenic composition wherein low levels of sICAM-1 indicate that the patient will develop a prophylactic or therapeutic response towards the immunogenic composition with low levels of sICAM-1 being fewer than 300 ng/ml, and wherein said immunogenic composition contains all or part of at least one targeted antigen or at least one recombinant vector expressing in vivo all or part of at least one heterologous nucleotide sequence encoding all or part of at least one targeted antigen. 
Postupak ispitivanja ex-vivo hoće li pacijent odgovoriti terapijski na postupak liječenja koji se sastoji u primjeni imunogenog pripravka, naznačen time što se postupak ispitivanja sastoji u koraku mjerenja razina sICAM-1 u uzorku krvi uzetom iz navedenog pacijenta prije primjene navedenog imunogenog pripravka, gdje niske razine sICAM-1 ukazuju da će pacijent razviti profilaktički ili terapijski odgovor na imunogeni pripravak kada su niske razine sICAM-1 ispod 300 ng/ml, te što navedeni imunogeni pripravak sadrži sve ili dio najmanje jednog ciljanog antigena ili najmanje jedan rekombinantni vektor koji in vivo eksprimira sve ili dio najmanje jednog heterolognog nukleotidnog slijeda koji kodira sve ili dio najmanje jednog ciljanog antigena.
The method of claim 1 wherein said low levels of sICAM-1 means levels of fewer than 200 ng/ml. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što navedene niske razine sICAM-1 znače razine ispod 200 ng/ml.
Antibody selected from: 
Antitijelo izabrano od:
a monoclonal antibody or an antigen-binding fragment thereof specific for human Fas ligand protein (FasL), wherein said monoclonal antibody comprises at least one heavy chain variable region and at least one light chain variable region, wherein the amino acid sequences of the complementary determining regions (CDRs) of the heavy chain are: 
Monoklonskog humanog antitijela ili njegovog antigen vežućeg fragmenta specifičnog za humani Fas-ligand protein (FasL), pri čemu navedeno monoklonsko antitijelo sadrži najmanje jednu varijabilnu regiju teškog lanca i najmanje jednu varijabilnu regiju lakog lanca i pri čemu su aminokiselinski sljedovi regija koje određuju komplementarnost (CDR) od teškog lanca:
a monoclonal antibody or an antigen-binding fragment thereof specific for human Fas ligand protein (FasL), wherein said monoclonal antibody comprises at least one heavy chain variable region and at least one light chain variable region, wherein the amino acid sequences of the complementary determining region (CDRs) of the heavy chain are: 
Monoklonskog humanog antitijela ili njegovog antigen vežućeg fragmenta specifičnog za humani Fas-ligand protein (FasL), pri čemu navedeno monoklonsko antitijelo sadrži najmanje jednu varijabilnu regiju teškog lanca i najmanje jednu varijabilnu regiju lakog lanca, pri čemu su aminokiselinski sljedovi regija koje određuju komplementarnost (CDR) od teškog lanca:
The antibody for use according to claim 4 in combination with at least one further immuno-suppressive drug, in particular with at least one further steroid. 
Antitijelo za uporabu u skladu sa zahtjevom 4 u kombinaciji s najmanje još jednim imunosupresivom, naročito s najmanje još jednim steroidom.
The packaging and the device for manual rolling of cigarettes as claimed in Claims 1 and 2, characterized in that variously shaped clamps may be arranged instead of the lugs (1f) and openings (1a'). 
Pakiranje i uređaj za ručno motanje cigareta, prema zahtjevu 1 i 2, naznačen/o time, da umjesto uha (1f) i otvora (1a'), mogu se rasporediti spone različitih oblika.
The packaging and the device for manual rolling of cigarettes as claimed in Claim 5, characterized in that variously shaped clamps may be arranged instead of the lugs (6g') and the openings (6a'). 
Pakiranje i uređaj za ručno motanje cigareta, prema zahtjevu 5, naznačen/o time, da umjesto uha (6g') i otvora (6a'), mogu se rasporediti spone različitih oblika.
The packaging and the device for manual rolling of cigarettes as claimed in Claim 9, characterized in that it can also be formed in a way that the base line (16) does not have the side (16a) and the side (16b). 
Pakiranje i uređaj za ručno motanje cigareta, prema zahtjevu 9, naznačen/o time, da može također biti oblikovan/o na takav način, da podna linija (16) ne sadrži stranu (16a) i stranu (16b).
The unit dose of claim 1, wherein the amount of Apadenoson present is 150 µg. 
Jedinična doza iz zahtjeva 1, pri čemu je količina prisutnog apadenozona 150 µg.
The unit dose of claim 1, wherein the pharmaceutical carrier includes β-hydroxypropyl-cyclodextrin. 
Jedinična doza iz zahtjeva 1, pri čemu farmaceutski nosač uključuje 8-hidroksipropil-ciklodekstrin.
The unit dose of claim 1, wherein the pH of the unit dose is selected from 4.6-5.0. 
Jedinična doza iz zahtjeva 1, pri čemu je pH jedinične doze izabrana između 4,6-5.
The unit dose of claim 5, wherein the pH is 4.8. 
Jedinična doza iz zahtjeva 5, pri čemu je pH 4,8.
The unit dose of claim 1, wherein the volume of the unit dose is selected from 1-5 mL. 
Jedinična doza iz zahtjeva 1, pri čemu je volumen jedinične doze izabran između 1-5 mL.
The unit dose of claim 1, wherein the volume of the unit dose is 2 mL, 3 mL, 4 mL or 5 mL. 
Jedinična doza iz zahtjeva 1, pri čemu je volumen jedinične doze 2, 3, 4 ili 5 mL.
The unit dose of claim 1, wherein the Apadenoson is 150 µg of Apadenoson and wherein the pharmaceutically acceptable carrier includes (i) 2% w/v HP-β-CD; (ii) sodium citrate buffer in an amount to buffer the unit dose to pH 4.8; and (iii) saline in an amount to form a 1-5 mL unit dose. 
Jedinična doza iz zahtjeva 1, pri čemu je apadenozon 150 µg apadenozona i pri čemu farmaceutski prihvatljivi nosač uključuje (i) 2% w/v HP-β-CD; (ii) natrijev citratni pufer u količini za namještanje pH jedinične doze na 4,8; (iii) fiziološku otopinu u količini za dobivanje jedinične doze od 1-5 mL.
The unit dose of claim 1, which is provided in a prefilled syringe. 
Jedinična doza iz zahtjeva 1 koja je dostupna u unaprijed napunjenoj injekciji.
A unit dose of Apadenoson according to any of claims 1 to 12, for use in a method of diagnosing myocardial perfusion abnormalities comprising: 
Jedinična doza apadenozona, prema bilo kojem od zahtjeva 1-12, za uporabu u metodi dijagnoze abnormalnosti kod miokardijalne perfuzije koja se sastoji od:
The unit dose for use according to claim 13, wherein the patient weighs at least 40 kg. 
Jedinična doza za uporabu prema zahtjevu 13, pri čemu pacijent teži najmanje 40 kg.
The monohydrochloride salt of the compound of formula (Ia) as defined in claim 1. 
Monohidrokloridna sol spoja formule (Ia), naznačena time što je spoj definiran kao u patentnom zahtjevu 1.
each R is independently hydrogen, C1-4 haloaliphatic, or C1-4 aliphatic; and PG3 is a suitable hydroxyl protecting group. A compound according to claim 9, wherein said suitable hydroxyl protecting group, taken with the oxygen atom to which it is bound, is selected from an ester, a silyl ether, an alkyl ether, an arylalkyl ether, and an alkoxyalkyl ether. 
svaki R je neovisno vodik, C1-4 haloalifatski, ili C1-4 alifatski; i PG3 je pogodna hidroksil zaštitna skupina, koja je zajedno s atomom kisika na koji je spojena, odabrana od estera, silil etera, alkil etera, arilalkil etera, te alkoksialkil etera.
the pharmaceutical composition comprises about 0.2% to about 3% of the compound of formula (I), or a crystalline form thereof, about 86.5% to about 99.8% of a filler, optionally up to about 1.5% of a lubricant, optionally up to about 5% of a flow-aid, and optionally up to about 5% of a buffer, by weight as a percentage of total weight; 
oko 0.2% do oko 3% spoja prema bilo kojem od patentnih zahtjeva 1 do 8, ili njegovog kristalnog oblika, oko 86.5% do oko 99.8% punitelja izborno do oko 1.5% lubrikanta, izborno do oko 5% aditiva za poboljšanje protoka, i izborno do oko 5% pufera, prema težini kao postotak ukupne težine;
ii) the pharmaceutical composition comprises about 0.2% to about 3% of the compound of formula (I), or a crystalline form thereof; about 97% to about 99.8% of a filler; and optionally up to about 1.5% of a lubricant, by weight as a percentage of total weight; 
oko 0.2% do oko 3% spoja prema bilo kojem od patentnih zahtjeva 1 do 8, ili njegovog kristalnog oblika; oko 97% do oko 99.8% punitelja; i izborno do oko 1.5% lubrikanta, prema težini kao postotak ukupne težine; ili
the lubricant, when present, is selected from the group consisting of magnesium stearate, glyceryl behenate, hydrogenated vegetable oil, talc, zinc stearate, calcium stearate, sucrose stearate, sodium stearyl fumarate, and mixtures thereof; 
lubrikant, kada je prisutan, je izabran iz grupe koju čine magnezijev stearat, gliceril behenat, hidrogenizirano biljno ulje, talk, cinkov stearat, kalcijev stearat, saharoza stearat, natrijev stearil fumarat, i njihove smjese, poželjno gdje lubrikant je magnezijev stearat; i/ili
xii) the flow-aid, when present, is talc; 
sredstvo za poboljšanje protočnosti, kada je prisutno, je talk.
A liquid pharmaceutical composition comprising a compound of any one of claims 1 to 11, a buffer, and optionally a tonicity modifier; optionally wherein the tonicity modifier, when present, is sodium chloride, and/or wherein the buffer is sodium citrate, and citric acid. 
Tekuća farmaceutska kompozicija koja sadrži spoj prema bilo kojem od patentnih zahtjeva 1 do 8, pufer i izborno modifikator toničnosti, izborno gdje modifikator toničnosti, kada je prisutan, je natrijev klorid i/ili gdje je pufer natrijev citrat, i limunska kiselina, poželjno gdje:
A method for preparing argatroban monohydrate comprising at least the steps of: 
Metoda pripreme aratroban monohidrata koja sadrži najmanje jedan korak od:
The method for preparing argatroban monohydrate according to claim 1, wherein the crystallization medium solvent is isopropanol. 
Metoda pripreme argatroban monohidrata prema zahtjevu 1, pri čemu je kristalizirajuće otapalo izopropanol.
The method for preparing argatroban monohydrate according to claim 1, wherein the crystallization or re-crystallization from methanol and water is achieved by subjecting the mass to the following temperature gradient: heating to 90-95ºC, maintenance at reflux temperature for a time between 1 and 3 hours, cooling to 70-75ºC in at least one hour and maintenance at this temperature for at least one hour, cooling to 20ºC in a time comprised between 2 and 6 hours and maintenance at this temperature for at least 6 hours. 
Metoda pripreme argatroban monohidrata prema zahtjevu 1, pri čemu je kristalizacija ili rekristalizacija iz metanolno-vodenog medija postignuta podvrgavanjem smjese sljedećem temperaturnom gradijentu: zagrijavanje na 90-95°C, održavanje na refluks temperaturi 1-3 sata, hlađenje na 70-75°C tijekom najmanje jednog sata i održavanje na toj temperaturi najmanje jedan sat, hlađenje na 20°C tijekom 2-6 sati i održavanje na toj temperaturi najmanje 6 sati.
The method for preparing argatroban monohydrate according to claim 1 further comprising the step of drying the obtained crystalline precipitate consisting of argatroban monohydrate. 
Metoda pripreme argatroban monohidrata prema zahtjevu 1 koja sadrži daljnji korak sušenja dobivenog kristaliničnog precipitata argatroban monohidrata.
re-crystallizing thereof after dissolution in water by quickly cooling to a temperature of 10-20ºC in a time not greater than 2 minutes. 
Njegova rekristalizacija, nakon otapanja u vodi, brzim hlađenjem na 10-20°C unutar ne više od 2 minute.
Purified argatroban characterized by having: 
Pročišćeni argatroban karakteriziran sljedećim parametrima:
A crystalline form of a tosylate salt of Compound 1: 
Kristalni oblik, naznačen time što je kristalni oblik tosilatne soli Spoja 1:
The polymorph of claim 2 obtained by crystallizing a tosylate salt of Compound 1: from isopropanol. 
Polimorf u skladu s patentnim zahtjevom 2, naznačen time što se dobiva kristaliziranjem tosilatne soli Spoja 1: [image] iz izopropanola.
dissolving p-toluenesulfonic acid in a second solvent or combination of solvents to form a second solution; 
otapanju p-toluensulfonske kiseline u drugom otapalu ili kombinaciji otapala kako bi se dobilo drugu otopinu;
combining the first and second solution to form a third solution; and adding a form 1 polymorph of a tosylate salt of Compound 1 as a seed crystal to the third solution to form a fourth solution. 
kombiniranju prve s drugom otopinom kako bi se dobilo treću otopinu; i dodavanju oblika 1 polimorfa tosilatne soli Spoja 1 kao kristala za zasijavanje u treću otopinu kako bi se dobilo četvrtu otopinu.
The method of claim 4, wherein the first combination of solvents and the second combination of solvents each comprises an alcoholic solvent, which is optionally methanol, and an anti-solvent, which is optionally selected from a ketone, an ester and an ether (e.g., methyl-t-butyl ether). 
Postupak u skladu s patentnim zahtjevom 4, naznačen time što svaka od prve kombinacije otapala i druge kombinacije otapale sadrži alkoholno otapalo, koje može biti metanol, te protuotapalo, koje se može birati između ketona, estera i etera (primjerice metil-t-butil-etera).
The method of claim 4, wherein the p-toluenesulfonic acid is provided in an amount of from 25 to 75 wt % relative to the amount of said Compound 1. 
Postupak u skladu s patentnim zahtjevom 4, naznačen time što se p-toluensulfonsku kiselinu dodaje u količini od 25 do 75%, težinski, u odnosu na količinu navedenog Spoja 1.
The polymorph of claim 15 obtained by crystallizing a tosylate salt of Compound 1: from dichloromethane. 
Polimorf u skladu s patentnim zahtjevom 15, naznačen time što se dobiva kristaliziranjem tosilatne soli Spoja 1:
a light chain (L-chain) comprising the amino acid sequence of SEQ ID NO:4 or 8. 
slabi lanac (L-lanac) koji sadrži aminokiselinsku sekvencu od SEQ ID NO:4 ili 8.
A pharmaceutical composition, comprising the antibody or the antigen-binding fragment according to any one of Claims 1 - 5 and a pharmaceutically acceptable carrier. 
Farmaceutski sastav, naznačen time, da obuhvaća protutijelo ili njegov fragment koji se veže na antigen, prema bilo kojem od zahtjeva 1 do 5, i farmaceutski prihvatljiv nosač.
The compound of claim 3, in a substantially crystalline form. 
Spoj prema patentnom zahtjevu 3, u značajno čistom kristalnom obliku.
and Z2 together form a moiety derived from citric acid, wherein the atom attached to boron in each case is an oxygen atom and wherein the moiety is formed by removing from citric acid a hydrogen atom from a carboxylic acid group and a hydrogen atom from the hydroxyl group directly attached to a carbon atom in an alpha or beta position relative to the carboxylic acid group. 
i Z2 zajedno formiraju grupu porijeklom iz limunske kiseline, gdje je atom vezan za bor u svakom slučaju atom kisika i gdje je grupa formirana uklanjanjem iz limunske kiseline atoma vodika iz grupe karboksilne kiseline i atoma vodika iz hidroksil grupe direktno vezanog za atom ugljika u alfa ili beta položaju u odnosu na grupu karboksilne kiseline.
The pharmaceutical composition of claim 9, comprising the compound as defined in any one of claims 1 to 8 or a crystalline form thereof, a filler and optionally a lubricant; wherein the pharmaceutical composition optionally further comprises a flow-aid, and optionally further comprises a buffer, optionally wherein the pharmaceutical composition is an oral pharmaceutical dosage form, for example a capsule. 
Farmaceutska kompozicija prema patentnom zahtjevu 9, koja sadrži spoj prema bilo kojem od patentnih zahtjeva 1 do 8 ili njegov kristalni oblik, punitelj i izborno lubrikant; pri čemu farmaceutska kompozicija izborno dalje sadrži aditiv za poboljšanje protoka, i izborno dalje sadrži pufer, izborno gdje je farmaceutska kompozicija oralni farmaceutski oblik doze, na primjer kapsula.
about 0.2% to about 3% of the compound as defined in any one of claims 1 to 8, or a crystalline form thereof, about 86.5% to about 99.8% of a filler, optionally up to about 1.5% of a lubricant, optionally up to about 5% of a flow-aid, and optionally up to about 5% of a buffer, by weight as a percentage of total weight; 
oko 0.2% do oko 3% spoja prema bilo kojem od patentnih zahtjeva 1 do 8, ili njegovog kristalnog oblika, oko 86.5% do oko 99.8% punitelja izborno do oko 1.5% lubrikanta, izborno do oko 5% aditiva za poboljšanje protoka, i izborno do oko 5% pufera, prema težini kao postotak ukupne težine;
about 0.2% to about 3% of the compound as defined in any one of claims 1 to 8, or a crystalline form thereof; about 97% to about 99.8% of a filler; and optionally up to about 1.5% of a lubricant, by weight as a percentage of total weight; or 
oko 0.2% do oko 3% spoja prema bilo kojem od patentnih zahtjeva 1 do 8, ili njegovog kristalnog oblika; oko 97% do oko 99.8% punitelja; i izborno do oko 1.5% lubrikanta, prema težini kao postotak ukupne težine; ili
the compound as defined in any one of claims 1 to 8 or a crystalline form thereof, is present in an amount of about 0.2% to about 3%, by weight as a percentage of total weight, for example an amount of about 0.25% to about 2%, by weight as a percentage of total weight; and/or 
spoj prema bilo kojem od patentnih zahtjeva 1 do 8 ili njegov kristalni oblik, je prisutan u količini od oko 0.2% do oko 3%, prema težini kao postotak ukupne težine, na primjer količina od oko 0.25% do oko 2%, prema težini kao postotak ukupne težine; i/ili
the filler is present in an amount of about 86.5% to about 99.8%, by weight as a percentage of total weight, for example wherein the filler is present in an amount of about 97% to about 99.8%, by weight as a percentage of total weight, or wherein the filler is present in an amount of about 98% to about 99.75%, by weight as a percentage of total weight; and/or 
punitelj je prisutan u količini od oko 86.5% do oko 99.8%, prema težini kao postotak ukupne težine, na primjer gdje je punitelj prisutan u količini od oko 97% do oko 99.8%, prema težini kao postotak ukupne težine, ili gdje je punitelj prisutan u količini od oko 98% do oko 99.75%, prema težini kao postotak ukupne težine; i/ili
wherein the lubricant, when present, is present in an amount of up to about 1.5%, by weight as a percentage of total weight, for example in an amount of about 1%, by weight as a percentage of total weight; and/or 
gdje je lubrikant, kada je prisutan, prisutan u količini do oko 1.5%, prema težini kao postotak ukupne težine, na primjer u količini od oko 1%, prema težini kao postotak ukupne težine; i/ili
the flow-aid, when present, is present in an amount of up to about 5%, by weight as a percentage of total weight, for example in an amount of about 1%, by weight as a percentage of total weight; and/or 
aditiv za poboljšanje protoka, kada je prisutan, je prisutan u količini do oko 5%, prema težini kao postotak ukupne težine, na primjer u količini od oko 1%, prema težini kao postotak ukupne težine; i/ili
the buffer, when present, is present in an amount of up to about 5%, by weight as a percentage of total weight, for example in an amount of about 2%, by weight as a percentage of total weight. 
pufer, kada je prisutan, je prisutan u količini do oko 5%, prema težini kao postotak ukupne težine, na primjer u količini od oko 2%, prema težini kao postotak ukupne težine.